Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Ubiquitin carboxy-terminal hydrolase L1 - physiology and pathology.

Matuszczak E, Tylicka M, Komarowska MD, Debek W, Hermanowicz A.

Cell Biochem Funct. 2020 Mar 24. doi: 10.1002/cbf.3527. [Epub ahead of print] Review.

PMID:
32207552
2.

Introduction to special section on: current topics in cancer survivorship and work.

de Boer AGEM, Greidanus MA, Dewa CS, Duijts SFA, Tamminga SJ.

J Cancer Surviv. 2020 Mar 23. doi: 10.1007/s11764-020-00868-w. [Epub ahead of print]

PMID:
32206965
3.

Cancer Incidence by Occupation in Korea: Longitudinal Analysis of a Nationwide Cohort.

Lee HE, Zaitsu M, Kim EA, Kawachi I.

Saf Health Work. 2020 Mar;11(1):41-49. doi: 10.1016/j.shaw.2019.12.004. Epub 2019 Dec 31.

4.

18F-Fluciclovine PET to distinguish treatment-related effects from disease progression in recurrent glioblastoma: PET fusion with MRI guides neurosurgical sampling.

Henderson F Jr, Brem S, O'Rourke DM, Nasrallah M, Buch VP, Young AJ, Doot RK, Pantel A, Desai A, Bagley SJ, Nabavizadeh SA.

Neurooncol Pract. 2020 Mar;7(2):152-157. doi: 10.1093/nop/npz068. Epub 2019 Dec 8.

5.

An Unusual Case of Simultaneous Cricoid and Thyroid Cartilage Metastases from Prostatic Adenocarcinoma on 68Ga-PSMA PET/CT.

Tupalli A, Damle NA, Thankarajan AS, Mangu BS, Kumar A, Khan D, Sagar S, Bal C.

Nucl Med Mol Imaging. 2020 Feb;54(1):61-62. doi: 10.1007/s13139-019-00625-7. Epub 2019 Dec 18.

PMID:
32206134
6.

Isolated Hepatic Metastasis of Prostate Cancer with Variable 18F-fluociclovine Uptake by PET/CT Imaging.

Sorra E, Aziz MU, Peng F.

Nucl Med Mol Imaging. 2020 Feb;54(1):53-57. doi: 10.1007/s13139-019-00623-9. Epub 2019 Nov 22.

PMID:
32206132
7.

Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy.

Liao Y, Liu Y, Xia X, Shao Z, Huang C, He J, Jiang L, Tang D, Liu J, Huang H.

Theranostics. 2020 Feb 10;10(8):3366-3381. doi: 10.7150/thno.41849. eCollection 2020.

8.

Muscarinic receptors promote castration-resistant growth of prostate cancer through a FAK-YAP signaling axis.

Goto Y, Ando T, Izumi H, Feng X, Arang N, Gilardi M, Wang Z, Ando K, Gutkind JS.

Oncogene. 2020 Mar 23. doi: 10.1038/s41388-020-1272-x. [Epub ahead of print]

PMID:
32205868
9.

Membrane metalloendopeptidase suppresses prostate carcinogenesis by attenuating effects of gastrin-releasing peptide on stem/progenitor cells.

Cheng CY, Zhou Z, Stone M, Lu B, Flesken-Nikitin A, Nanus DM, Nikitin AY.

Oncogenesis. 2020 Mar 23;9(3):38. doi: 10.1038/s41389-020-0222-3.

10.

Oligometastatic and Oligoprogression Disease and Local Therapies in Prostate Cancer.

Deek MP, Tran PT.

Cancer J. 2020 Mar/Apr;26(2):137-143. doi: 10.1097/PPO.0000000000000432.

PMID:
32205538
11.

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors.

Isakoff SJ, Tabernero J, Molife LR, Soria JC, Cervantes A, Vogelzang NJ, Patel MR, Hussain M, Baron A, Argilés G, Conkling PR, Sampath D, Maslyar D, Patel P, Chan W, Gendreau S, Musib L, Xu N, Ma H, Lin K, Bendell J.

Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36054-3. doi: 10.1016/j.annonc.2020.02.007. [Epub ahead of print]

12.

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.

Kolinsky MP, Rescigno P, Bianchini D, Zafeiriou Z, Mehra N, Mateo J, Michalarea V, Riisnaes R, Crespo M, Figueiredo I, Miranda S, Nava Rodrigues D, Flohr P, Tunariu N, Banerji U, Ruddle R, Sharp A, Welti J, Lambros M, Carreira S, Raynaud FI, Swales KE, Plymate S, Luo J, Tovey H, Porta N, Slade R, Leonard L, Hall E, de Bono JS.

Ann Oncol. 2020 Feb 21. pii: S0923-7534(20)36037-3. doi: 10.1016/j.annonc.2020.01.074. [Epub ahead of print]

13.

William Halsted and Prostate Cancer Progression.

Albertsen PC.

Eur Urol. 2020 Mar 21. pii: S0302-2838(20)30148-2. doi: 10.1016/j.eururo.2020.03.007. [Epub ahead of print] No abstract available.

PMID:
32204944
14.

Cell Stress Induced Stressome Release Including Damaged Membrane Vesicles and Extracellular HSP90 by Prostate Cancer Cells.

Eguchi T, Sogawa C, Ono K, Matsumoto M, Tran MT, Okusha Y, Lang BJ, Okamoto K, Calderwood SK.

Cells. 2020 Mar 19;9(3). pii: E755. doi: 10.3390/cells9030755.

15.

Development of Novel 111-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid Tumours.

Poret B, Desrues L, Bonin MA, Pédard M, Dubois M, Leduc R, Modzelewski R, Decazes P, Morin F, Vera P, Castel H, Bohn P, Gandolfo P.

Biomolecules. 2020 Mar 19;10(3). pii: E471. doi: 10.3390/biom10030471.

16.

Exosomes in Prostate Cancer Diagnosis, Prognosis and Therapy.

Lorenc T, Klimczyk K, Michalczewska I, Słomka M, Kubiak-Tomaszewska G, Olejarz W.

Int J Mol Sci. 2020 Mar 19;21(6). pii: E2118. doi: 10.3390/ijms21062118. Review.

17.

Magnetic nanoparticles for amalgamation of magnetic hyperthermia and chemotherapy: An approach towards enhanced attenuation of tumor.

Singh A, Jain S, Sahoo SK.

Mater Sci Eng C Mater Biol Appl. 2020 May;110:110695. doi: 10.1016/j.msec.2020.110695. Epub 2020 Jan 28.

PMID:
32204010
18.

A New Nomogram Allowing Physicians to Predict Patients at High Risk of Fever Occurring After Prostate Biopsy.

Xia H, Wang H, Chen L, Meng J, Zhou J, Liang C.

Med Sci Monit. 2020 Mar 22;26:e921350. doi: 10.12659/MSM.921350.

19.

The Calculus of Serum PSA.

Vollmer RT.

Am J Clin Pathol. 2019 Aug 1;152(3):365-368. doi: 10.1093/ajcp/aqz042.

PMID:
31139828

Supplemental Content

Loading ...
Support Center